German pharmaceutical company BioNTech was back in profit in the third quarter of 2024, it announced on Monday, with comparatively early approvals for adapted coronavirus vaccines driving up sales.

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...

MODERNA reported a surprise third-quarter profit on Thursday (Nov 7), driven by cost cutting and higher-than-expected sales ...

For RNA viruses that mutate frequently, like COVID-19 and influenza, manufacturers ... data with Moderna’s personalised melanoma vaccine and BioNTech is due to present data on its mRNA-shared ...

BioNTech and Pfizer will continue to monitor the evolving epidemiology of COVID-19 and remain prepared to develop modified vaccine formulas as the data support and as regulatory agencies recommend.

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Results from a randomized control trial published Nov. 6 in JAMA Network Open show that participants who received mRNA ...

Barnstable County Department of Health and Environment’s Public Health Nursing Division will conduct its second public COVID-19/flu clinic on Wednesday, November 20, from 10 AM to 1 PM in the ...